Tag: surrogate endpoint
-
Finerenone across CKM stages — the relative effect is flat, the absolute benefit is not, and the new endpoint moves its own goalposts
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. A post hoc analysis of 12,990 people with type 2 diabetes and chronic kidney disease from two phase 3 trials, pooled and then re-classified using the…
Uthando Nethemba 